Disease overview Chronic lymphocytic leukemia (CLL) is one of the most frequent types of
leukemia. It typically occurs in elderly patients and has a highly variable clinical course …

The previous edition of the consensus guidelines of the International Workshop on Chronic
Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by …

Background Venetoclax plus obinutuzumab has been established as a fixed-duration
treatment regimen for patients with chronic lymphocytic leukaemia. We compared the long …

Background The BCL2 inhibitor venetoclax has shown activity in patients with chronic
lymphocytic leukemia (CLL), but its efficacy in combination with other agents in patients with …

Background Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of
B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic …

PURPOSE The CLL14 study has established one-year fixed-duration treatment of
venetoclax and obinutuzumab (Ven-Obi) for patients with previously untreated chronic …

Summary Background Therapy targeting Bruton's tyrosine kinase (BTK) with ibrutinib has
transformed the treatment of chronic lymphocytic leukaemia. However, patients who are …

Important advances in understanding the pathogenesis of chronic lymphocytic leukaemia in
the past two decades have led to the development of new prognostic tools and novel …

Abstract Disease Overview Chronic lymphocytic leukemia (CLL) is the commonest leukemia
in western countries. The disease typically occurs in elderly patients and has a highly …

Accurate identification of patients likely to achieve long-progression-free survival (PFS) after
chemoimmunotherapy is essential given the availability of less toxic alternatives, such as …